drugset / Trial / NCT01722968
A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel
RandomizedParallel-groupOpen-labelTreatment
Summary
To explore molecular biomarkers and/or gene expression signatures that predict response to bevacizumab given in combination with paclitaxel as first line therapy in HER2 negative metastatic breast cancer (MBC).
Timeline
- Start
- 2012-11
- Primary completion
- 2018-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Comparator | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |